A Study of Long-Term Responders on Olaparib

Inclusion Criteria

• •Previous or current treatment with Olaparib in a clinical trial/standard of care that included one of the following as a first step study for epithelial ovarian cancer (including fallopian tube or peritoneal cancer):
• •* single agent olaparib given for relapsed disease or
• •* single agent olaparib given as maintenance therapy after response to platinum based chemotherapy or
• •* olaparib combined with platinum based chemotherapy and then continued as maintenance therapy or
• •* olaparib combined with other types of therapy
• •Had a durable response to Olaparib defined as patients who have benefited from olaparib for \> 18 months. Patients who discontinued Olaparib due to toxicities but otherwise meet the definition of a durable response will be included or the control group is patients who had a short duration benefit with Olaparib of less than 6 months in any individual clinical trial/standard of care
• •Ability to understand and the willingness to sign a written informed consent document.
• •Patient's willingness and ability to comply with scheduled visits, laboratory tests, and other study procedures.